{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023345","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2026-05-15T12:00:31+00:00","discovered_at":"2026-05-15T12:05:00.218088+00:00","generated_at":"2026-05-15T12:07:02.044012+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M","bullets":["Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.","Raised gross $2.8M in Q1; subsequent $1.5M from warrant exercises and $5M upfront from $13.9M private placement.","As of May 15, cash balance approx $10.3M; expects to fund EB-003 activities into Q1 2027.","Advancing EB-003 toward IND; new preclinical data including PTSD model with rapid fear response reduction.","AbbVie withdrew PGR petition against Enveric patent covering bretisilocin; strengthens IP portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023345","json":"https://secwatch.observer/filing/0001493152-26-023345.json","markdown":"https://secwatch.observer/filing/0001493152-26-023345.md","text":"https://secwatch.observer/filing/0001493152-26-023345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/0001493152-26-023345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:07:02.044012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02fd98d862c3da8c41cd6508a68e0b1faede898a","claim":"Enveric Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss attributable to stockholders was $1.6 million, EPS basic and diluted loss per share of $1.08.","evidence_excerpt":"Net loss attributable to stockholders was $1.6 million for the first quarter ended March 31, 2026, including $0.1 million in net non-cash expense, with a basic and diluted loss per share of $1.08","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/0001493152-26-023345-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss attributable to stockholders was $1.6 million"},{"label":"EPS","value":"basic and diluted loss per share of $1.08"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fb4359970a5d14d4f98448362ebaac921d6828d1","claim":"Enveric Biosciences, Inc. reported the quarter ended March 31, 2025 results: net income net loss of $2.2 million, EPS basic and diluted loss per share of $14.58.","evidence_excerpt":"as compared to a net loss of $2.2 million, including $0.3 million in net non-cash income, with a basic and diluted loss per share of $14.58 for the quarter ended March 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/0001493152-26-023345-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2025"},{"label":"Net income","value":"net loss of $2.2 million"},{"label":"EPS","value":"basic and diluted loss per share of $14.58"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}